LNAINasdaqPharmaceutical PreparationsFiscal year ends June 30

Lunai Bioworks Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Oct 13, 2026

$0.47−0.21 (-30.63%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Lunai Bioworks Inc. balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30	FY 2018 2018-06-30	FY 2017 2017-06-30	FY 2014 2014-12-31	FY 2012 2012-03-31	FY 2011 2011-03-31
Cash & Equivalents	1.71	0.09	0.22	1.87	9.17	21	8.70	12	16	3.94	3.01	0.00	0
Cash & Short-Term Investments	1.71	0.09	0.22	1.53	8.81	20	8.16	12	16	3.69	3.01	0.00	0
Prepaid Expenses & Other	–	–	0.67	–	0.39	0.23	0.24	0.19	0.04	0.03	–	–	–
Total Current Assets	2.04	1.05	2.00	2.57	9.57	21	8.94	12	16	4.20	5.05	0.01	0
Property, Plant & Equipment	0.01	0.37	0.48	0.51	0.59	0.72	0.78	0.69	0.03	–	–	–	–
Gross Property, Plant & Equipment	0.02	1.07	1.06	0.97	0.94	0.98	0.93	0.75	0.26	0.23	0.24	–	–
Accumulated Depreciation	-0.01	-0.70	-0.58	-0.46	-0.36	-0.26	-0.15	-0.06	-0.23	-0.23	0.24	–	–
Operating Lease Right-of-Use Assets	–	0.69	1.27	0.91	1.16	1.44	1.70	1.96	–	–	–	–	–
Goodwill	5.96	5.96	159	12	12	12	12	12	12	–	–	–	–
Intangible Assets	1.41	0.17	0.03	0.04	0.04	0.07	0.08	0.09	0.11	0.12	0.19	–	–
Other Long-Term Assets	7.89	6.82	161	55	74	168	168	–	–	–	–	–	–
Total Assets	9.94	8.23	163	58	85	190	178	180	183	4.52	5.24	0.01	0
Accounts Payable	–	–	–	–	–	–	–	–	–	–	0.71	–	–
Accrued Expenses	5.02	5.84	5.31	0.72	1.03	1.18	0.47	0.34	0.07	0.23	0.73	–	–
Current Portion of Long-Term Debt	–	–	–	–	–	–	–	–	–	–	0.10	–	–
Current Debt	–	–	–	–	–	–	–	–	–	–	0.10	–	–
Current Portion of Leases	0.29	0.31	0.49	0.19	0.25	0.29	0.27	–	–	–	–	–	–
Other Current Liabilities	0.18	0.38	0.30	0.18	0.22	0.09	0	–	–	–	–	–	–
Total Current Liabilities	19	29	30	11	6.45	1.89	1.33	1.11	0.87	2.99	1.76	0.03	0.01
Long-Term Debt	–	–	–	–	4.58	4.58	4.58	–	–	–	–	–	–
Long-Term Leases	0.06	0.42	0.84	0.78	0.99	1.24	1.53	–	–	–	–	–	–
Operating Lease Liabilities	0.35	0.74	1.34	0.97	1.24	1.53	1.80	2.05	–	–	–	–	–
Other Long-Term Liabilities	0.15	0.27	0.23	0.18	0.17	–	–	–	–	–	–	–	–
Total Liabilities	19	30	31	12	12	15	12	6.78	24	2.99	1.76	0.03	0.01
Total Debt	–	–	–	–	4.58	4.58	4.58	–	–	–	0.10	–	–
Preferred Stock	0	0	0	0	–	0	0	–	–	–	–	0	0
Common Stock	0.00	0.00	0.02	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Additional Paid-In Capital	505	478	465	291	277	266	230	226	193	30	25	0.02	0.02
Retained Earnings	-514	-510	-332	-244	-204	-91	-64	-53	-35	-28	-22	–	–
Comprehensive Income & Other	-0.16	11	-0.17	-0.03	-0.03	-0.01	-0.04	0.10	0.21	0.35	0.28	–	–
Shareholders' Equity	-9.02	-21	132	47	73	175	166	173	159	1.53	3.48	-0.01	-0.01
Total Equity	-9.02	-21	132	47	73	175	166	173	159	1.53	3.48	-0.01	-0.01
Total Liabilities & Equity	9.94	8.23	163	58	85	190	178	180	183	4.52	5.24	0.01	0
Shares Outstanding(shares)	4.62	2.22	16	6.37	5.30	5.22	4.65	4.53	3.62	1.24	0.95	0.50	0.50

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -16729.4%
Net margin: -6852.0%
Return on equity, FY2026: 23.5%

Financial strength

Current ratio: 0.11
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 9.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –